|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.36 CNY | 0.00% |
|
-0.64% | -34.50% |
Business description: Chongqing Zhifei Biological Products Co., Ltd.
Number of employees: 6,292
Sales by Activity: Chongqing Zhifei Biological Products Co., Ltd.
| Fiscal Period: December | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|
Biochemical Product | 30.63B | 38.26B | 52.91B | 25.85B | 8.87B |
Unallocated Others | 23.46M | 3.85M | 4.08M | 223M | 90.42M |
Geographical breakdown of sales: Chongqing Zhifei Biological Products Co., Ltd.
| Fiscal Period: December | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|
Eastern China | 9.55B | 12.99B | 18.48B | 8.49B | 2.61B |
South China | 4.36B | 7.53B | 9B | 4.37B | 1.91B |
Southwest China | 4.12B | 5.04B | 7.23B | 4.36B | 1.29B |
Central China | 4.77B | 5.59B | 6.48B | 3.08B | 1.21B |
North China | 4.7B | 4.05B | 6.99B | 3.22B | 1.04B |
Northwest China | 1.11B | 1.64B | 3.07B | 1.61B | 540M |
Northeast China | 890M | 1.44B | 1.66B | 921M | 327M |
Export | 1.16B | -463K | 9.23M | 17.7M | 34.7M |
Executive Committee: Chongqing Zhifei Biological Products Co., Ltd.
| Manager | Title | Age | Since |
|---|---|---|---|
Ling Feng Jiang
CEO | Chief Executive Officer | 46 | 2024-09-19 |
Zhen Jing Li
DFI | Director of Finance/CFO | 44 | 2015-08-18 |
Dan Qing Leng
CMP | Compliance Officer | 40 | 2011-12-31 |
Jie Shao
CTO | Chief Tech/Sci/R&D Officer | 39 | 2020-12-31 |
Lin Du
CTO | Chief Tech/Sci/R&D Officer | 61 | 2017-04-10 |
Composition of the Board of Directors: Chongqing Zhifei Biological Products Co., Ltd.
| Director | Title | Age | Since |
|---|---|---|---|
Xin Rong Zhang
BRD | Director/Board Member | 67 | 2015-05-14 |
Ren Sheng Jiang
CHM | Chairman | 73 | 2009-08-16 |
Ling Feng Jiang
BRD | Director/Board Member | 46 | 2018-08-09 |
Lin Du
BRD | Director/Board Member | 61 | 2017-04-10 |
Fei Qin
BRD | Director/Board Member | 40 | 2009-12-31 |
Zhen Jing Li
BRD | Director/Board Member | 44 | 2018-04-09 |
Lin Yuan
BRD | Director/Board Member | 62 | 2014-04-30 |
Tao Gong
BRD | Director/Board Member | 57 | 2021-09-16 |
Shi Long Yang
BRD | Director/Board Member | 63 | 2018-08-09 |
Company details: Chongqing Zhifei Biological Products Co., Ltd.
Chongqing Zhifei Biological Products Co., Ltd.
50/F, 1 Yunlu Road
400020, Chongqing
+86 23 8635 8685
http://www.zhifeishengwu.com
Biopharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -0.64% | -34.81% | -72.04% | 4.37B | |
| +0.08% | -3.67% | +15.66% | -20.62% | 62.28B | |
| -5.78% | -0.73% | +59.99% | +205.54% | 60.59B | |
| +0.70% | +29.50% | +29.50% | +29.50% | 39.55B | |
| -1.84% | +6.09% | -55.86% | -62.24% | 36.8B | |
| -1.29% | +2.41% | +53.12% | -33.31% | 29.53B | |
| -5.00% | +6.01% | +60.19% | +76.64% | 21.68B | |
| +1.11% | +5.21% | +87.14% | -60.40% | 19.8B | |
| +1.24% | +5.67% | -3.61% | +127.98% | 16.96B | |
| -0.89% | -1.67% | +51.28% | +98.64% | 16.16B | |
| Average | -1.13% | +3.10% | +26.26% | +28.97% | 30.77B | |
| Weighted average by Cap. | -1.60% | +2.96% | +29.04% | +42.17% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 300122 Stock
- Company Chongqing Zhifei Biological Products Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition